{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T11:16:23Z","timestamp":1790766983888,"version":"4.1.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T00:00:00Z","timestamp":1574208000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81370284"],"award-info":[{"award-number":["81370284"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81700294"],"award-info":[{"award-number":["81700294"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Experimental and clinical trials have demonstrated the efficiency of bone marrow-derived mesenchymal stromal\/stem cells (bMSCs) in the treatment of myocardial infarction. However, after intravenous injection, the ineffective migration of engrafted bMSCs to the hearts remains an obstacle, which has an undesirable impact on the efficiency of cell-based therapy. Therefore, we attempted to identify a marker that could distinguish a subpopulation of bMSCs with a promising migratory capacity.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>Here, CD51-negative and CD51-positive cells were isolated by flow cytometry from Ter119<jats:sup>\u2212<\/jats:sup>CD45<jats:sup>\u2212<\/jats:sup>CD31<jats:sup>\u2212<\/jats:sup>bMSCs and cultured in specifically modified medium. The proliferation ability of the cells was evaluated by 5-ethynyl-2\u2032-deoxyuridine (EdU) staining or continuously monitored during culture, and the differentiation potential was assessed by culturing the cells in the appropriate conditioned media. Wound healing assays, transwell assays and quantitative polymerase chain reaction (qPCR) were used to measure the migratory ability. The mice were subjected to a sham operation or myocardial infarction (MI) by permanently occluding the coronary artery, and green fluorescent protein (GFP)-labelled cells were transplanted into the mice via intravenous infusion immediately after MI. Heart function was measured by echocardiography; infarct myocardium tissues were detected by triphenyl tetrazolium chloride (TTC) staining. Additionally, immunofluorescence staining was used to verify the characteristics of CD51<jats:sup>+<\/jats:sup>bMSCs and inflammatory responses in vivo. Statistical comparisons were performed using a two-tailed Student\u2019s <jats:italic>t<\/jats:italic> test.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>In this study, the isolated CD51<jats:sup>\u2212<\/jats:sup>bMSCs and CD51<jats:sup>+<\/jats:sup>bMSCs, especially the CD51<jats:sup>+<\/jats:sup> cells, presented a favourable proliferative capacity and could differentiate into adipocytes, osteocytes and chondrocytes in vitro. After the cells were transplanted into the MI mice by intravenous injection, the therapeutic efficiency of CD51<jats:sup>+<\/jats:sup>bMSCs in improving left ventricular ejection fraction (LVEF) and left ventricular fractional shortening (LVFS) was better than that of CD51<jats:sup>\u2212<\/jats:sup>bMSCs. Compared with CD51<jats:sup>\u2212<\/jats:sup>bMSCs, CD51<jats:sup>+<\/jats:sup>bMSCs preferentially migrated to and were retained in the infarcted hearts at 48\u2009h and 8\u2009days after intravenous injection. Accordingly, the migratory capacity of CD51<jats:sup>+<\/jats:sup>bMSCs exceeded that of CD51<jats:sup>\u2212<\/jats:sup>bMSCs in vitro, and the former cells expressed higher levels of chemokine receptors or ligands. Interestingly, the retained CD51<jats:sup>+<\/jats:sup>bMSCs retained in the myocardium possessed proliferative potential but only differentiated into endothelial cells, smooth muscle cells, fibroblasts or cardiomyocytes. Transplantation of CD51<jats:sup>+<\/jats:sup>bMSCs partially attenuated the inflammatory response in the hearts after MI, while the potential for inflammatory suppression was low in CD51<jats:sup>\u2212<\/jats:sup>bMSC-treated mice.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>These findings indicated that the CD51-distinguished subpopulation of bMSCs facilitated proliferation and migration both in vitro and in vivo, which provided a novel cell-based strategy to treat acute MI in mice by intravenous injection.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13287-019-1439-y","type":"journal-article","created":{"date-parts":[[2019,11,20]],"date-time":"2019-11-20T09:03:18Z","timestamp":1574240598000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CD51 distinguishes a subpopulation of bone marrow mesenchymal stem cells with distinct migratory potential: a novel cell-based strategy to treat acute myocardial infarction in mice"],"prefix":"10.1186","volume":"10","author":[{"given":"Dong-Mei","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuansheng","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juhong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5715-2078","authenticated-orcid":false,"given":"Xiuren","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,20]]},"reference":[{"issue":"4","key":"1439_CR1","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici M, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315\u20137.","journal-title":"Cytotherapy"},{"issue":"1","key":"1439_CR2","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/0008-5472.CAN-16-3507","volume":"78","author":"S Rossnagl","year":"2018","unstructured":"Rossnagl S, et al. A subpopulation of stromal cells controls cancer cell homing to the bone marrow. Cancer Res. 2018;78(1):129\u201342.","journal-title":"Cancer Res"},{"issue":"9","key":"1439_CR3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1089\/scd.2015.0344","volume":"25","author":"S Pacini","year":"2016","unstructured":"Pacini S, et al. Mesangiogenic progenitor cells derived from one novel CD64(bright)CD31(bright)CD14(neg) population in human adult bone marrow. Stem Cells Dev. 2016;25(9):661\u201373.","journal-title":"Stem Cells Dev"},{"issue":"29","key":"1439_CR4","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","volume":"37","author":"MF Piepoli","year":"2016","unstructured":"Piepoli MF, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315\u201381.","journal-title":"Eur Heart J"},{"issue":"5","key":"1439_CR5","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.tcm.2016.01.003","volume":"26","author":"A Terzic","year":"2016","unstructured":"Terzic A, Behfar A. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc Med. 2016;26(5):395\u2013404.","journal-title":"Trends Cardiovasc Med"},{"key":"1439_CR6","doi-asserted-by":"publisher","first-page":"308185","DOI":"10.1155\/2015\/308185","volume":"2015","author":"C Schmidt-Lucke","year":"2015","unstructured":"Schmidt-Lucke C, et al. Cardiac migration of endogenous mesenchymal stromal cells in patients with inflammatory cardiomyopathy. Mediat Inflamm. 2015;2015:308185.","journal-title":"Mediat Inflamm"},{"issue":"19","key":"1439_CR7","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1089\/scd.2014.0269","volume":"23","author":"MJ Hoogduijn","year":"2014","unstructured":"Hoogduijn MJ, et al. No evidence for circulating mesenchymal stem cells in patients with organ injury. Stem Cells Dev. 2014;23(19):2328\u201335.","journal-title":"Stem Cells Dev"},{"issue":"4","key":"1439_CR8","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/j.yjmcc.2007.11.001","volume":"44","author":"Y Imanishi","year":"2008","unstructured":"Imanishi Y, et al. Allogenic mesenchymal stem cell transplantation has a therapeutic effect in acute myocardial infarction in rats. J Mol Cell Cardiol. 2008;44(4):662\u201371.","journal-title":"J Mol Cell Cardiol"},{"issue":"9429","key":"1439_CR9","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0140-6736(04)16626-9","volume":"364","author":"KC Wollert","year":"2004","unstructured":"Wollert KC, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141\u20138.","journal-title":"Lancet"},{"issue":"39","key":"1439_CR10","doi-asserted-by":"publisher","first-page":"2936","DOI":"10.1093\/eurheartj\/ehx188","volume":"38","author":"KC Wollert","year":"2017","unstructured":"Wollert KC, et al. Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial. Eur Heart J. 2017;38(39):2936\u201343.","journal-title":"Eur Heart J"},{"issue":"2","key":"1439_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.3727\/096368909X479677","volume":"19","author":"AC Assis","year":"2010","unstructured":"Assis AC, et al. Time-dependent migration of systemically delivered bone marrow mesenchymal stem cells to the infarcted heart. Cell Transplant. 2010;19(2):219\u201330.","journal-title":"Cell Transplant"},{"issue":"7","key":"1439_CR12","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1161\/01.CIR.0000084828.50310.6A","volume":"108","author":"IM Barbash","year":"2003","unstructured":"Barbash IM, et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 2003;108(7):863\u20138.","journal-title":"Circulation"},{"issue":"6","key":"1439_CR13","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1172\/JCI113548","volume":"81","author":"DM Sosnoski","year":"1988","unstructured":"Sosnoski DM, et al. Chromosomal localization of the genes for the vitronectin and fibronectin receptors alpha subunits and for platelet glycoproteins IIb and IIIa. J Clin Invest. 1988;81(6):1993\u20138.","journal-title":"J Clin Invest"},{"issue":"1","key":"1439_CR14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(92)90115-S","volume":"69","author":"RO Hynes","year":"1992","unstructured":"Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69(1):11\u201325.","journal-title":"Cell"},{"issue":"7","key":"1439_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1084\/jem.20122252","volume":"210","author":"S Pinho","year":"2013","unstructured":"Pinho S, et al. PDGFRalpha and CD51 mark human nestin+ sphere-forming mesenchymal stem cells capable of hematopoietic progenitor cell expansion. J Exp Med. 2013;210(7):1351\u201367.","journal-title":"J Exp Med"},{"issue":"12","key":"1439_CR16","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1038\/cr.2014.149","volume":"24","author":"MH Jiang","year":"2014","unstructured":"Jiang MH, et al. Characterization of Nestin-positive stem Leydig cells as a potential source for the treatment of testicular Leydig cell dysfunction. Cell Res. 2014;24(12):1466\u201385.","journal-title":"Cell Res"},{"issue":"5","key":"1439_CR17","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1002\/stem.2569","volume":"35","author":"Zhi Jun Zang","year":"2017","unstructured":"Zang ZJ, et al. Transplantation of CD51+ stem Leydig cells: a new strategy for the treatment of testosterone deficiency. Stem Cells. 2017;35(5):1222-32.","journal-title":"STEM CELLS"},{"issue":"7","key":"1439_CR18","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1634\/stemcells.2004-0013","volume":"22","author":"Hwai-Shi Wang","year":"2004","unstructured":"Wang HS, et al. Mesenchymal stem cells in the Wharton\u2019s jelly of the human umbilical cord. Stem Cells. 2004;22(7):1330\u20137.","journal-title":"Stem Cells"},{"issue":"4","key":"1439_CR19","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/ijos.2015.42","volume":"7","author":"R Alvarez","year":"2015","unstructured":"Alvarez R, et al. Characterization of the osteogenic potential of mesenchymal stem cells from human periodontal ligament based on cell surface markers. Int J Oral Sci. 2015;7(4):213\u20139.","journal-title":"Int J Oral Sci"},{"issue":"8","key":"1439_CR20","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.V83.8.2103.2103","volume":"83","author":"SJ Thoma","year":"1994","unstructured":"Thoma SJ, Lamping CP, Ziegler BL. Phenotype analysis of hematopoietic CD34+ cell populations derived from human umbilical cord blood using flow cytometry and cDNA-polymerase chain reaction. Blood. 1994;83(8):2103\u201314.","journal-title":"Blood"},{"issue":"5","key":"1439_CR21","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41419-018-0541-x","volume":"9","author":"X Sui","year":"2018","unstructured":"Sui X, et al. p53-dependent CD51 expression contributes to characteristics of cancer stem cells in prostate cancer. Cell Death Dis. 2018;9(5):523.","journal-title":"Cell Death Dis"},{"key":"1439_CR22","doi-asserted-by":"crossref","unstructured":"Spata T, et al. \u201cA nonthoracotomy myocardial infarction model in an ovine using autologous platelets.\u201d BioMed research international. 2013;(2013):7.","DOI":"10.1155\/2013\/938047"},{"issue":"4","key":"1439_CR23","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1161\/CIRCRESAHA.116.304899","volume":"116","author":"Q Wang","year":"2015","unstructured":"Wang Q, et al. Receptor-interacting protein kinase 3 contributes to abdominal aortic aneurysms via smooth muscle cell necrosis and inflammation. Circ Res. 2015;116(4):600\u201311.","journal-title":"Circ Res"},{"issue":"1","key":"1439_CR24","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s12015-011-9293-z","volume":"8","author":"Y Wu","year":"2012","unstructured":"Wu Y, Zhao RC. The role of chemokines in mesenchymal stem cell homing to myocardium. Stem Cell Rev. 2012;8(1):243\u201350.","journal-title":"Stem Cell Rev"},{"issue":"3","key":"1439_CR25","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0002-9440(10)62289-4","volume":"166","author":"BB Moore","year":"2005","unstructured":"Moore BB, et al. CCR2-mediated recruitment of fibrocytes to the alveolar space after fibrotic injury. Am J Pathol. 2005;166(3):675\u201384.","journal-title":"Am J Pathol"},{"issue":"11","key":"1439_CR26","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1089\/wound.2014.0579","volume":"4","author":"AM Hocking","year":"2015","unstructured":"Hocking AM. The role of chemokines in mesenchymal stem cell homing to wounds. Adv Wound Care (New Rochelle). 2015;4(11):623\u201330.","journal-title":"Adv Wound Care (New Rochelle)"},{"issue":"10","key":"1439_CR27","doi-asserted-by":"publisher","first-page":"596","DOI":"10.3858\/emm.2011.43.10.069","volume":"43","author":"SJ Baek","year":"2011","unstructured":"Baek SJ, Kang SK, Ra JC. In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. Exp Mol Med. 2011;43(10):596\u2013603.","journal-title":"Exp Mol Med"},{"issue":"5","key":"1439_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2017.138","volume":"8","author":"K Chen","year":"2017","unstructured":"Chen K, et al. Human MSCs promotes colorectal cancer epithelial-mesenchymal transition and progression via CCL5\/beta-catenin\/Slug pathway. Cell Death Dis. 2017;8(5):e2819.","journal-title":"Cell Death Dis"},{"issue":"3","key":"1439_CR29","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.stemcr.2017.01.016","volume":"8","author":"R Chen","year":"2017","unstructured":"Chen R, et al. Epigenetic modification of the CCL5\/CCR1\/ERK axis enhances glioma targeting in dedifferentiation-reprogrammed BMSCs. Stem Cell Reports. 2017;8(3):743\u201357.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"1439_CR30","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.stemcr.2019.04.023","volume":"13","author":"SO Piryani","year":"2019","unstructured":"Piryani SO, et al. CCR5 signaling promotes murine and human hematopoietic regeneration following ionizing radiation. Stem Cell Reports. 2019;13(1):76\u201390.","journal-title":"Stem Cell Reports"},{"key":"1439_CR31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13045-016-0236-7","volume":"9","author":"Z Tu","year":"2016","unstructured":"Tu Z, et al. CCR9 in cancer: oncogenic role and therapeutic targeting. J Hematol Oncol. 2016;9:10.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"1439_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1182\/blood-2009-08-237784","volume":"115","author":"DA Zlotoff","year":"2010","unstructured":"Zlotoff DA, et al. CCR7 and CCR9 together recruit hematopoietic progenitors to the adult thymus. Blood. 2010;115(10):1897\u2013905.","journal-title":"Blood"},{"issue":"3","key":"1439_CR33","doi-asserted-by":"publisher","DOI":"10.4161\/2162402X.2014.990767","volume":"4","author":"L Lu","year":"2015","unstructured":"Lu L, et al. Cancer stem cell vaccine inhibits metastases of primary tumors and induces humoral immune responses against cancer stem cells. Oncoimmunology. 2015;4(3):e990767.","journal-title":"Oncoimmunology"},{"issue":"7","key":"1439_CR34","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41419-018-0745-0","volume":"9","author":"L Du","year":"2018","unstructured":"Du L, et al. CXCR1\/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis. Cell Death Dis. 2018;9(7):714.","journal-title":"Cell Death Dis"},{"issue":"4","key":"1439_CR35","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1084\/jem.20161616","volume":"214","author":"BW Blaser","year":"2017","unstructured":"Blaser BW, et al. CXCR1 remodels the vascular niche to promote hematopoietic stem and progenitor cell engraftment. J Exp Med. 2017;214(4):1011\u201327.","journal-title":"J Exp Med"},{"key":"1439_CR36","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1038\/ncomms2766","volume":"4","author":"Y Jung","year":"2013","unstructured":"Jung Y, et al. Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis. Nat Commun. 2013;4:1795.","journal-title":"Nat Commun"},{"issue":"10","key":"1439_CR37","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1161\/CIRCULATIONAHA.105.537480","volume":"112","author":"DL Kraitchman","year":"2005","unstructured":"Kraitchman DL, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation. 2005;112(10):1451\u201361.","journal-title":"Circulation"},{"issue":"8","key":"1439_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.104.500447","volume":"112","author":"N Nagaya","year":"2005","unstructured":"Nagaya N, et al. Transplantation of mesenchymal stem cells improves cardiac function in a rat model of dilated cardiomyopathy. Circulation. 2005;112(8):1128\u201335.","journal-title":"Circulation"},{"issue":"9","key":"1439_CR39","doi-asserted-by":"publisher","first-page":"H1354","DOI":"10.1152\/ajpheart.00379.2013","volume":"305","author":"K Igura","year":"2013","unstructured":"Igura K, et al. Identification of small juvenile stem cells in aged bone marrow and their therapeutic potential for repair of the ischemic heart. Am J Physiol Heart Circ Physiol. 2013;305(9):H1354\u201362.","journal-title":"Am J Physiol Heart Circ Physiol"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-019-1439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13287-019-1439-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-019-1439-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:25:55Z","timestamp":1605745555000},"score":1,"resource":{"primary":{"URL":"https:\/\/stemcellres.biomedcentral.com\/articles\/10.1186\/s13287-019-1439-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,20]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1439"],"URL":"https:\/\/doi.org\/10.1186\/s13287-019-1439-y","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,20]]},"assertion":[{"value":"18 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All surgical procedures and animal care protocols in the present study were approved by the Laboratory Animal Research Committee of Sun Yat-sen University.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"331"}}